Walgreens Boots Alliance agreed in March 2025 to be acquired by private equity firm Sycamore Partners, a deal that would end the pharmacy company's run as a publicly traded business after years of pressure on prescription economics, retail performance and its balance sheet.
The agreement called for Walgreens Boots Alliance shareholders to receive $11.45 per share in cash, plus a non-transferable right that could provide up to an additional $3.00 per share from the future monetization of the company's interests in VillageMD businesses. Walgreens said the transaction represented total potential value of up to $23.7 billion.
What the Sycamore deal offered Walgreens shareholders
Under the agreement announced on March 6, 2025, shareholders were entitled to $11.45 per share in cash when the transaction closed. They were also due one Divested Asset Proceed Right for each share, potentially worth up to another $3.00 in cash depending on future proceeds from Walgreens Boots Alliance's interests in VillageMD, Summit Health and CityMD.
Walgreens said the $11.45 cash consideration represented a 29% premium to its closing share price of $8.85 on December 9, 2024, the day before initial media reports about a potential transaction. Including the maximum potential value of the additional right, the company calculated the premium at up to 63% relative to that unaffected share price.
The full transaction terms were detailed in Walgreens Boots Alliance's acquisition announcement.
Why Walgreens was pursuing a turnaround
The proposed sale came after a difficult period for Walgreens and the broader U.S. retail pharmacy industry. Pharmacy operators had been dealing with reimbursement pressure, rising operating costs and intense competition in front-of-store retail from large chains and online sellers.
Walgreens had already begun shrinking its store footprint. In October 2024, the company said it expected to close approximately 1,200 locations over three years, including about 500 in fiscal 2025. The program was designed to concentrate investment on stronger locations while removing stores that were weighing on profitability and cash flow.
The company's financial statements also showed how sharply reported results had deteriorated. Walgreens Boots Alliance recorded a fiscal 2024 net loss attributable to the company of approximately $8.6 billion, compared with a $3.1 billion loss in fiscal 2023.
That headline loss did not simply reflect day-to-day pharmacy operations. Walgreens' fiscal 2024 Form 10-K shows that results included major non-cash impairment and tax-related charges, including impairment associated with VillageMD and other assets. The company also cited reimbursement pressure and a challenging U.S. retail environment among the factors affecting its operating performance.
Private ownership was presented as a way to accelerate change
At the time of the acquisition announcement, Walgreens Boots Alliance CEO Tim Wentworth said the company was making progress on its turnaround but argued that the scale of the changes required would be easier to manage away from the public markets.
For Sycamore, the deal added one of the largest pharmacy and health-and-beauty businesses in the United States and United Kingdom to a portfolio built around consumer, retail and distribution investments. Sycamore had previously invested in companies including Staples, Ann Taylor and other retail brands.
The agreement initially remained subject to shareholder approval, regulatory approvals and other customary closing conditions. Walgreens said in March 2025 that it expected the transaction to close in the fourth quarter of calendar 2025.
The pharmacy industry's broader pressure
Walgreens' challenges were not occurring in isolation. Major U.S. drugstore operators had been reducing store counts and restructuring as the traditional pharmacy model came under pressure from lower reimbursement economics, changing shopping habits and competition from mass merchants and e-commerce businesses.
That environment made store productivity increasingly important. Closing weaker locations could reduce expenses, but Walgreens still had to maintain convenient pharmacy access for customers while improving the economics of its remaining network.
The acquisition therefore represented more than a change in ownership. It gave Walgreens a route to continue restructuring outside the quarterly expectations of public equity markets while Sycamore took on the challenge of improving a large, complicated healthcare and retail operation.
Later context: the acquisition was completed in August 2025
Walgreens' original timetable changed as the transaction progressed. Shareholders approved the acquisition in July 2025, and Sycamore completed its acquisition of Walgreens Boots Alliance on August 28, 2025, earlier than the fourth-quarter closing window initially discussed.
Following completion, Walgreens Boots Alliance common stock ceased trading and was removed from Nasdaq. Shareholders received the agreed $11.45-per-share cash consideration together with the non-transferable right tied to potential future proceeds from VillageMD interests.
The ownership structure also changed significantly after closing. Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD were set to operate as separate standalone companies under private ownership. Walgreens itself announced that former Staples U.S. Retail chief Mike Motz would become its chief executive, replacing Wentworth, who remained involved as a director.
The completed transaction and post-closing structure were confirmed in Walgreens' August 28, 2025 announcement.
What the deal ultimately meant
The Sycamore acquisition removed Walgreens Boots Alliance from the public markets and shifted its turnaround into a private-equity ownership structure. The central business challenge, however, remained much the same: improving pharmacy economics, concentrating resources on productive stores, controlling costs and restoring sustainable performance across businesses that had faced very different competitive pressures.
For former public shareholders, the final economic value could extend beyond the $11.45 cash payment because of the additional right linked to future VillageMD monetization. How much value that right ultimately produces depends on future asset proceeds, so the maximum additional $3.00 per share was never guaranteed.
0 Comments